@article{3123911, title = "Crocus sativus L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals", author = "Christodoulou, E. and Kadoglou, N.P.E. and Stasinopoulou, M. and Konstandi, O.A. and Kenoutis, C. and Kakazanis, Z.I. and Rizakou, A. and Kostomitsopoulos, N. and Valsami, G.", journal = "Atherosclerosis", year = "2018", volume = "268", pages = "207-214", publisher = "Elsevier Ireland Ltd", issn = "0021-9150", doi = "10.1016/j.atherosclerosis.2017.10.032", keywords = "antidiabetic agent; antiinflammatory agent; autacoid; biological marker; Crocus vernus agglutinin; mannose binding lectin; matrix metalloproteinase; plant extract; plant lectin; triacylglycerol, animal; aorta; aortic disease; apolipoprotein E knockout mouse; atherosclerosis; atherosclerotic plaque; blood; C57BL mouse; chemistry; dose response; drug effect; experimental diabetes mellitus; genetics; glucose blood level; isolation and purification; lipid diet; male; metabolism; pathology; rupture, Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Atherosclerosis; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Dose-Response Relationship, Drug; Hypoglycemic Agents; Inflammation Mediators; Male; Mannose-Binding Lectins; Matrix Metalloproteinases; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plant Extracts; Plant Lectins; Plaque, Atherosclerotic; Rupture, Spontaneous; Triglycerides", abstract = "Background and aims We aimed to evaluate a possible atheroprotective effect of saffron aqueous extract (SFE), and its potential anti-inflammatory mechanisms, in apoE knockout (ApoE−/−) mice. Methods Fifty male, ApoE−/− mice, fed a high-fat diet (HFD) for 12 weeks, were randomized into 5 groups: (1) baseline group, euthanatized, without intervention, (2) three saffron groups, receiving HFD and 30,60,90 mg/kg/day of SFE, respectively, for four weeks, per os through gavage, after reconstitution in water for injection (WFI), (3) control group (COG), receiving daily HFD and the same volume of WFI (four weeks). After blood sampling and euthanasia, aortic roots were excised and analyzed for gene expression and/or percentage of aortic stenosis, relative content of macrophages, smooth muscle cells (SMCs), connective tissue, tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinases-2,-3,-9 (MMP-2,-3,-9) and their inhibitor (TIMP-2) and IL-6. SFE doses were determined by a pilot serum pharmacokinetic study in C57BL/6J wild-type mice. Results SFE did not affect body weight and total cholesterol levels (p > 0.05), while high SFE dose significantly ameliorated glucose and triglycerides profiles compared to other groups (p < 0.05). SFE considerably decreased aortic stenosis in a dose-dependent manner (p < 0.05). Furthermore, increasing SFE doses proportionally reduced macrophages content and increased within plaques content of collagen, elastin, and SMCs, promoting more stable plaque phenotype compared to COG (p < 0.05). Those effects seemed to be associated with a considerable reduction (>30%) in IL-6, TNF-α MCP-1, MMP-2,-3,-9 (p < 0.05) and MMP-2/TIMP-2 ratio. Conclusions SFE exerted dose-dependent anti-atherosclerotic and plaque-stabilizing effects in Apo-E−/− mice, probably mediated by a favorable modification of inflammatory mechanisms, which requires further investigation. © 2017 Elsevier B.V." }